Anti-HBV activity of TRL mediated by recombinant adenovirus

World Journal of Gastroenterology

Volumn 11, Issue 17, 2005, Pages 2574-2578

  Gong, Wei Dong ^a   Zhao, Ya ^b   Yi, Jun ^c   Ding, Jin ^b   Liu, Jun ^b   Xue, Cai Fang ^b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

HVB; HVB TRL

Indexed keywords

ADENOVIRUS VECTOR; ANTIVIRUS AGENT; CORE PROTEIN; PROTEIN TRL; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS PROTEIN;

ADENOVIRUS; ANTIVIRAL ACTIVITY; ARTICLE; CELL METABOLISM; CELL STRAIN HEK293; CELL STRAIN HEPG2; COLORIMETRY; CONTROLLED STUDY; DNA CONTENT; GENE SEQUENCE; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IN VIVO STUDY; PLASMID; PROTEIN ANALYSIS; PROTEIN DETERMINATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS EXPRESSION; VIRUS INHIBITION; VIRUS RECOMBINANT; VIRUS REPLICATION;

EID: 18944388410     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i17.2574     Document Type: Article

References (29)

1. Fleming J. Current treatments for hepatitis. J Infus Nurs 2002; 25: 379-382
2. Elsaadany S, Tepper M, Mao Y, Semenciw R, Giulivi A. An epidemiologic study of hepatocellular carcinoma in Canada. Can J Public Health 2002; 93: 443-446
3. Hassan MM, Hwang LY, Hatten CJ, Swaim M, Li D, Abbruzzese JL, Beasley P, Patt YZ. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002; 36: 1206-1213
4. Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis 2002; 2: 479-486
5. Lok AS. Prevention of hepatitis B virus-related hepatocellular carcinoma. Gastroenterology 2004; 127(5 Suppl 2): S303-309
6. Mazumdar TN. Management of chronic hepatitis B infection: an update. J Indian Med Assoc 2001; 99: 306-308
7. Chen N, Zhu C, Hu D, Zeng F. The clinical significance of negative serological markers of hepatitis B infection in hepatitis B virus carriers with chronic hepatic disease. Zhonghua Neike Zazhi 2002; 41: 653-655
8. Hino O, Kajino K, Umeda T, Arakawa Y. Understanding the hypercarcinogenic state in chronic hepatitis: a clue to the prevention of human hepatocellular carcinoma. J Gastroenterol 2002; 37: 883-887
9. Esteban R. Management of chronic hepatitis B: an overview. Semin Liver Dis 2002; 22(Suppl 1): 1-6
10. Wai CT, Chu CJ, Hussain M, Lok AS. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology 2002; 36: 1425-1430
11. Manns MP. Current state of interferon therapy in the treatment of chronic hepatitis B. Semin Liver Dis 2002; 22(Suppl 1): 7-14
12. Shindo M, Hamada K, Koya S, Sokawa Y, Okuno T. The clinical significance of core promoter and precore mutations during the natural course and interferon therapy in patients with chronic hepatitis B. Am J Gastroenterol 1999; 94: 2237-2245
13. Liaw YF. Therapy of chronic hepatitis B: current challenges and opportunities. J Viral Hepat 2002; 9: 393-399
14. Wolters LM, Hansen BE, Niesters HG, de Man RA. Viral dynamics in chronic hepatitis B patients treated with lamivudine, lamivudine-famciclovir or lamivudine-ganciclovir. Eur J Gastroenterol Hepatol 2002; 14: 1007-1011
15. Song JW, Zhang G, Lin JG, Tang WX, Lin JS. Clinical study of lamivudine and interferon combinate administration to inhibit hepatitis B virus replication. Zhonghua Ganzangbing Zazhi 2004; 12: 593-596
16. Chiou HC, Lucas MA, Coffin CC, Banaszczyk MG, III CR, Lollo CP. Gene therapy strategies for the treatment of chronic viral hepatitis. Expert Opin Biol Ther 2001; 1: 629-639
17. Natsoulis G, Boeke JD. New antiviral strategy using capsid-nuclease fusion proteins. Nature 1991; 352: 632-635
18. Schumann G, Hermankova M, Cannon K, Mankowski JL, Boeke JD. Therapeutic effect of a Gag-nuclease fusion protein against retroviral infection in vivo. J Virol 2001; 75: 7030-7041
19. Qin CF, Qin ED. Development of cell lines stably expressing staphylococcal nuclease fused to dengue 2 virus capsid protein for CTVI. Acta Biochim Biophys Sin 2004; 36: 577-582
20. Beterams G, Nassal M. Significant interference with hepatitis B virus replication by a core-nuclease fusion protein. J Biol Chem 2001; 276: 8875-8883
21. Li YH, Liu J, Xue CF. Construction of HBV targeted-ribonuclease and ies expression in 2.2.15 cell line. Xibaoyu Fenzi Mianyixue Zazhi 2001; 17: 549-551
22. Ding J, Liu J, Xue CF, Li YH, Gong WD. Construction and expression of prokaryotic expression vector for pTAT-HBV targeted ribonuclease fusion protein. Xibaoyu Fenzi Mianyixue Zazhi 2003; 19: 49-51
23. Gong WD, Liu J, Ding J, Zhao Y, Li YH, Xue CF. Optimizing HBV targeted ribonuclease by introduction of linker. Disi Junyi Daxue Xuebao 2003; 24: 1011-1013
24. Zhao Y, Liu J, Gong WD, Li YH, Ding J, Xue CF. Expression of fusion protein gene of HBV core protein and human eosinophil derived neurotoxin mediated by recombinant adenovirus in mouse liver. Disi Junyi Daxue Xuebao 2004; 25: 1073-1076
25. Zhao Y, Gong WD, Liu J, Li YH, Ding J, Xue CF. Construction of the HBV-TR recombinant adenovirus vector. Disi Junyi Daxue Xuebao 2004; 25: 321-324
26. Raj V. Treatment of hepatitis B. Clin Cornerstone 2001; 3: 24-36
27. Martin FS, Heike O, Heinz S. Transfer of hepatitis B virus genome by adenovirus vectors into cultured cells and mice: Crossing the species barrier. J Virol 2001; 75: 5108-5118
28. Nilsson M, Ljungberg J, Richter J, Kiefer T, Magnusson M, Lieber A, Widegren B, Karlsson S, Fan X. Development of an adenoviral vector system with adenovirus serotype 35 tropism; efficient transient gene transfer into primary malignant hematopoietic cells. J Gene Med 2004; 6: 631-641
29. Zeng M, Smith SK, Siegel F, Shi Z, Van Kampen KR, Elmets CA, Tang DC. AdEasy system made easier by selecting the viral backbone plasmid preceding homologous recombination. Biotechniques 2001; 31: 260-262